Combination therapy with proteasome inhibitors and TLR agonists enhances tumour cell death and IL-1β production

Proteasome inhibitors have emerged as an effective therapy for the treatment of haematological malignancies; however, their efficacy can be limited by the development of tumour resistance mechanisms. Novel combination strategies including the addition of TLR adjuvants to increase cell death and augm...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Anthony C, Rahavi, Seyed M, Fung, Shan-Yu, Lu, Henry Y, Yang, Hong, Lim, Chinten J, Reid, Gregor S, Turvey, Stuart E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833743/
https://www.ncbi.nlm.nih.gov/pubmed/29415982
http://dx.doi.org/10.1038/s41419-017-0194-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833743/
https://www.ncbi.nlm.nih.gov/pubmed/29415982
http://dx.doi.org/10.1038/s41419-017-0194-1

Ejemplares similares